74 Participants Needed

UPLYFT for Lymphoma

OO
Overseen ByOreofe O Odejide, MD, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Dana-Farber Cancer Institute
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the UPLYFT treatment for lymphoma?

Research shows that fear of cancer recurrence is a common issue for cancer patients, including those with lymphoma, and addressing this fear can improve quality of life. Similar treatments, like ConquerFear and FoRtitude, have been effective in reducing fear of recurrence in cancer survivors, suggesting that UPLYFT may also help lymphoma patients manage their fears.12345

What makes the UPLYFT treatment unique for lymphoma?

UPLYFT is unique because it focuses on addressing the fear of cancer recurrence, which is a psychological aspect not typically targeted by standard lymphoma treatments that primarily focus on physical symptoms and disease progression.678910

Research Team

OO

Oreofe O Odejide, MD, PhD

Principal Investigator

Oreofe_Odejide@dfci.harvard.edu

Eligibility Criteria

This trial is for adults over 18 who have been treated for lymphoma and are in remission but still experience significant fear of cancer recurrence. They must be within 3 to 24 months post-treatment, have access to a computer, and not have other untreated major psychiatric disorders or concurrent malignancies.

Inclusion Criteria

I finished my first lymphoma treatment between 3 and 24 months ago.
Lymphoma Survivors Phase 1 and 2: Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale [FCRI-SS)
I am in complete remission from lymphoma after my first treatment.
See 5 more

Exclusion Criteria

Our study will exclude members of the following special populations: Prisoners
I do not have untreated mental health conditions like psychosis, bipolar, or borderline personality disorder.
I do not have untreated mental health conditions like psychosis, bipolar, or borderline personality disorder.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Development

Development of the UPLYFT program based on feedback from clinicians and a field test with lymphoma survivors

Varies

Intervention

Lymphoma survivors participate in the finalized UPLYFT program consisting of 6 weekly sessions

6 weeks
6 visits (in-person or virtual)

Follow-up

Participants are monitored for changes in psychological inflexibility, depression, fear of cancer recurrence, quality of life, and anxiety

Up to 6 months

Treatment Details

Interventions

  • UPLYFT
Trial OverviewUPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) is being tested. It's an intervention designed to help lymphoma survivors improve their quality of life by providing information on survivorship and tools to manage worries about the disease returning.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: UPLYFT PilotExperimental Treatment1 Intervention
Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program. Participants will be randomized 1:1 to either UPLYFT or usual care.
Group II: Lymphoma Survivors Field TestExperimental Treatment1 Intervention
A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.
Group III: Clinicians InterviewsExperimental Treatment1 Intervention
Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials
1,128
Recruited
382,000+

American Society of Hematology

Collaborator

Trials
14
Recruited
20,800+

Findings from Research

Fear of cancer recurrence or progression is a common and significant concern for cancer patients, impacting their quality of life and emotional well-being.
Early recognition and support for this fear, along with referrals to psychosocial oncology, can improve patient outcomes and help identify those at risk during key points in their treatment journey.
Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?Bergerot, CD., Philip, EJ., Bergerot, PG., et al.[2022]
About 16.3% of lymphoma patients experienced severe fear of cancer recurrence (FCR) after completing treatment, which was linked to a significantly higher risk of all-cause mortality (hazard ratio of 2.52) and lymphoma-specific mortality (hazard ratio of 2.62).
Patients with severe FCR reported worse quality of life, including lower scores in general health and various functioning areas, indicating that managing FCR is crucial for improving patient outcomes post-treatment.
Impact of fear of cancer recurrence on survival among lymphoma patients.Kim, SJ., Kang, D., Kim, IR., et al.[2020]
The targeted eHealth intervention 'FoRtitude' significantly reduced fear of recurrence (FoR) in breast cancer survivors, with scores decreasing from an average of 53.1 to 41.9 after the intervention, indicating its efficacy in addressing this prevalent concern.
Telecoaching enhanced participant adherence to the program and reduced dropout rates, suggesting that remote support can improve engagement in eHealth interventions for cancer survivors.
Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results From the FoRtitude Randomized Trial.Wagner, LI., Tooze, JA., Hall, DL., et al.[2022]

References

Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It? [2022]
Impact of fear of cancer recurrence on survival among lymphoma patients. [2020]
Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results From the FoRtitude Randomized Trial. [2022]
Fear of Progression in Cancer Patients and Survivors. [2019]
Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. [2017]
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. [2022]
Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. [2020]
Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma. [2019]
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. [2017]
All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma. [2022]